|
|
|
27.04.26 - 05:30
|
S.Korea Trade Minister on Trade, Supply-chain expansion (Bloomberg)
|
|
|
South Korea's stock markets are showing strong gains in the Asia session, with the COSPI index up about 1%, led by technology companies such as Samsung and SK Hynix, which constitute around 40% of the index. The COSPI has surged over 150% in the past year, outperforming many global markets, particularly due to the AI boom. South Korea's trade minister, Yeo Han-Koo, discussed the country's robust export performance despite global headwinds including rising protectionism, energy supply disruptions, and geopolitical tensions such as the ongoing war in Iran. The minister highlighted the pivotal role of AI-driven exports in sustaining South Korea's economic growth while emphasizing the need to diversify markets and supply chains to mitigate risks.
Original filename: 20260427_014301_South_Korea_s_AI_Driven_Export_Boom_Fuels_Market_Gains_Amid_.mp4 (Source: Bloomberg)...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24.04.26 - 21:45
|
Samsung Epis Holdings gibt Finanzergebnisse für das erste Quartal 2026 bekannt (Business Wire)
|
|
|
Samsung Bioepis verzeichnete im ersten Quartal 2026 einen Umsatz von 454,9 Mrd. KRW und einen Betriebsgewinn von 144,0 Mrd. KRW
INCHEON, Korea--(BUSINESS WIRE)--Samsung Epis Holdings (KRX: 0126Z0), eine Investmentgesellschaft, die sich auf Innovationen in den Bereichen Biopharmazeutika und Biotechnologie spezialisiert hat, gab heute ihre Finanzergebnisse für das erste Quartal des Geschäftsjahres 2026 bekannt.
„Samsung Bioepis verzeichnete in diesem Quartal ein solides Wachstum, das von der anhaltenden Dynamik unseres Biosimilar-Portfolios getragen wurde“, sagte Kyung-Ah Kim, Präsidentin und Chief Executive Officer (CEO) von Samsung Epis Holdings. „Wir stärken unsere Position durch neue globale Partnerschaften und die kontinuierliche Erweiterung unseres Portfolios weiter. Anlässlich des 10. Jahrestags der Markteinführung unseres ersten Biosimilars in Europa konzentrieren wir uns weiterhin darauf, auf unserem Erbe aufzubauen und gleichzeitig strategisch zu investieren, um langfristiges Wachstum ...
|
|
|
|
|
|
|
|
|
|
|
|
|
24.04.26 - 07:09
|
CORRECTING and REPLACING Samsung Epis Holdings Reports First Quarter 2026 Financial Results (Business Wire)
|
|
|
Samsung Bioepis recorded Q1'26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion
INCHEON, Korea--(BUSINESS WIRE)--#ADC--Third paragraph, second sentence of release should read: Revenue and operating profit in the first quarter increased by 14% (KRW 54.3 billion) and 13% (KRW 16.1 billion) in year-over-year (YoY), respectively. (instead of Revenue and operating profit in the fourth quarter increased by 14% (KRW 54.3 billion) and 13% (KRW 16.1 billion) in year-over-year (YoY), respectively.).
The updated release reads:
SAMSUNG EPIS HOLDINGS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026.
“Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epi...
|
|
|
|
|
|
|
|
|
|